Antibiotics for Digestive System/ GI: 73.2% of denials overturned
In 56 California IMR decisions from 2003 to 2025, reviewers overturned 41 (73.2%). In the last five years: 85.7% of 14. 54 were medical-necessity disputes, 2 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 3 | 66.7% |
| 2022 | 1 | 100.0% |
| 2023 | 2 | 50.0% |
| 2024 | 3 | 100.0% |
| 2025 | 5 | 100.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 33 | 81.8% | 73.2% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 7 | 100.0% | 73.2% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 5 | 0.0% | 73.2% |
| FDA approval or off-label use discussedThe findings discuss the FDA label status of the treatment. | 3 | 66.7% | 73.2% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Xifaxan. Xifaxan has proven highly effective in patients with small intestinal bacterial overgrowth for the eradication of bacteria and symptom relief. Per the medical records, the patient’s testing results are consistent with small intestinal bacterial overgrowth. Given that current medical literature supports …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary:A patient has requested authorization and coverage for rifaximin for the treatment of irritable bowel syndrome with diarrhea. Rifaximin is a U.S. Food and Drug Administration (FDA)-approved therapy for this condition, and clinical guidelines support its use as an effective treatment option. Medical literature demonstrates that rifaximin can improve symptoms in …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for rifaximin (Xifaxan). Xifaxan has proven highly effective in patients with small intestinal bacterial overgrowth for the eradication of bacteria and symptom relief, and is the preferred agent among clinicians for treating small intestinal bacterial overgrowth. Per the medical records, testing results are …”
And one the reviewer upheld
“The physician reviewer found that The parents of a pediatric patient requested authorization and coverage for Xifaxan tablets for the treatment of irritable bowel syndrome.Xifaxan may be considered in the treatment of pediatric patients with a diagnosis of small intestinal bacterial overgrowth (SIBO). However, Xifaxan is not typically recommended for the treatment of IBS in pediatric patients absent a SIBO …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Antibiotics denials for Digestive System/ GI overturned?
In 56 California IMR decisions from 2003 to 2025, reviewers overturned 41 (73.2%). In the last five years: 85.7% of 14. 54 were medical-necessity disputes, 2 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.